• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Bioventus Inc.

    12/23/24 5:35:51 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001204391
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Bioventus Inc.
    SEC File Number
    001-37844
    Address of Issuer
    4721 EMPEROR BOULEVARD, SUITE 100
    DURHAM
    NORTH CAROLINA
    27703
    Phone
    (919) 474-6700
    Name of Person for Whose Account the Securities are To Be Sold
    CHURCH KATRINA J
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    E-Trade / Morgan Stanley Smith Barney LLC
    200 W. Civic Center Drive, 4th Floor
    Sandy � UT � 84070
    800089200.006536783012/23/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock03/14/2022Grant of Restricted Stock UnitsIssuerCheckbox not checked345603/14/2022Employee Compensation
    Common Stock06/20/2023Grant of Restricted Stock UnitsIssuerCheckbox not checked860006/20/2023Employee Compensation
    Common Stock03/15/2024Grant of Restricted Stock UnitsIssuerCheckbox not checked437503/15/2024Employee Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Part of Issuer sell to cover program
    Date of Notice
    12/23/2024
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/20/2023

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Anthony D'Adamio, Attorney-in-Fact

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $BVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    11/9/2022Overweight → Underweight
    JP Morgan
    3/15/2022$30.00Buy
    Craig Hallum
    3/11/2022$20.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives.

      1/7/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. converted options into 26,493 shares, increasing direct ownership by 58% to 72,045 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/5/25 9:22:27 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Sutter Martin P converted options into 26,493 shares, increasing direct ownership by 45% to 85,241 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/4/25 9:30:50 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Director Stalnecker Susan M converted options into 26,493 shares, increasing direct ownership by 33% to 105,957 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      6/4/25 9:30:40 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Financials

    Live finance-specific insights

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

      DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web

      10/29/24 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      8/20/24 6:16:00 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Bioventus Appoints Mark Singleton as Chief Financial Officer

      DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si

      2/28/22 7:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus Appoints Michelle McMurry-Heath to Board of Directors

      DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex

      12/21/21 9:25:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    SEC Filings

    See more
    • Bioventus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Bioventus Inc. (0001665988) (Filer)

      6/4/25 4:16:09 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Bioventus Inc.

      SD - Bioventus Inc. (0001665988) (Filer)

      6/2/25 5:10:41 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bioventus Inc.

      10-Q - Bioventus Inc. (0001665988) (Filer)

      5/6/25 7:38:47 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      11/8/24 9:13:26 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      7/15/24 5:15:58 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      2/14/24 4:51:41 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bioventus upgraded by Analyst with a new price target

      Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

      12/17/24 7:32:13 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00

      12/7/23 6:14:32 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Bioventus from Hold to Buy and set a new price target of $6.00 from $4.00 previously

      8/9/23 7:43:55 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care